An update on treatment options for primary sclerosing cholangitis

Shahrokh Iravani1,2, Arash Dooghaie-Moghadam3, Niloofar Razavi-Khorasani3, Bobak Moazzami3, Amirreza Dowlati Beirami4, Alireza Mansour-Ghanaei2, Keivan Majidzadeh-A1, Azim Mehrvar1, Alireza Khoshdel1, Mohssen Nasiri Toosi3, Amir Sadeghi4

1Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran
2Gastroenterology and Hepatobiliary Research Center, AJA University of Medical Sciences, Tehran, Iran
3Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
4Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT
Primary sclerosing cholangitis is a chronic cholestatic liver disease defined by strictures of the biliary tree which could ultimately lead to liver cirrhosis and cholangiocarcinoma. Although the exact underlying etiology of this disorder is not fully understood, the pathology is believed to be caused by immune mediated mechanisms. Growing body of evidence suggests several treatment modalities mainly focusing on the inflammation aspect of this disorder. However, there is still no consensus regarding the best treatment option for these patients. Thus, the present study aimed to review the current treatment options for patients with primary sclerosing cholangitis.

Keywords: Inflammatory bowel disease, Primary sclerosing cholangitis (PSC), Management, Vancomycin, Cholestasis, Cholangitis.

Introduction
Primary Sclerosing Cholangitis (PSC) is a rare but serious, chronic cholestatic fibroinflammatory liver disease characterized by progressive and multifocal fibrosis of the biliary system, which typically results in cirrhosis and fibrotic liver diseases (1-3). PSC is associated with several comorbidities such as Inflammatory bowel disease (IBD), which results in a phenotypically different disease, PSC-IBD, which differs from PSC in management. PSC also significantly increases the risk of developing malignant comorbidities such as cholangiocarcinoma (CCA), hepatocellular carcinoma (HCC), gallbladder carcinoma (GBC), and colorectal carcinoma (CRC) (4). Prevalence of PSC differs from 1 to 16 per 100,000 in different societies, and its incidence differs from 1 to 1.3 cases per 100,000 (4, 5). Approximately 70% of patients with PSC have underlying IBD, and prevalence of PSC-IBD has been estimated 24 per 100,000, though the statistics are not accurate because of the varying diagnostic criteria (5).

The prolonged duration of IBD in PSC-IBD patients seemingly increases the risk of developing CCA and CRC (6, 7). Annually, 0.5% to 1.5% of patients with PSC develop CCA with the lifetime incidence of GBC and HCC in patients with PSC estimated to be 3%-14% and 0.3%-8%, respectively. There is insufficient data about pancreatic cancer, but it is suggested to be 14 times higher than the healthy population in PSC patients (4). Altogether, the frequency of hepatobiliary
malignancies in patients with PSC is estimated 13% (8).

Due to PSCs complications and comorbidities as well as their high rate of mortality, early diagnosis of it and its comorbidities is important as it provides more time to determine the best tactics for treatment of PSC, prevention and/or early detection of the comorbidities, as well as management of malignancies in early stages (4, 5, 9, 10). Clinical symptoms such as fatigue, pruritus, and jaundice can be a result of PSC but the major problem with PSC diagnosis is that it is often not clinically symptomatic. Further, unlooked-for findings of impaired biliary ducts on imaging or asymptomatic elevation of hepatic biomarkers such as alkaline phosphatase are more common diagnostics in PSC diagnosis (1). Finally, the diagnosis of PSC can be confirmed by cholangiography. On the other hand, many experts recommend regular magnetic resonance imaging with magnetic resonance cholangiopancreatography (MRI/MRCP) which potentially improves the outcome for CCA, as the most common malignancy of PSC (1, 3, 4, 11). In this article, we will review the potential and current drug therapies for treating and modifying the complications of PSC and their efficacy based on clinical trial studies.

Pathophysiology of PSC

The main causes of PSC have remained unknown so far. According to the results of the prevalence of PSC, environmental factors and genetic polymorphisms may play an important role in the disease prevalence. Recently, part of the abnormal composition of gut flora, genetic susceptibility, and immune system dysfunction have attracted researchers' attention (12-14). Cholangitis or inflammation of the bile ducts is the main characteristic of PSC disease. Development of these inflammatory reactions can induce scar formation in these ducts and subsequently, the biliary tract narrows; eventually, the bile ducts get blocked with the PSC progression (15).

Blocked bile ducts lead to an increased susceptibility to progressive biliary fibrosis, biliary cirrhosis, and eventually liver failure. Inflammation of the bile ducts and scars in these ducts can make the patient susceptible to cholangiocarcinoma. Also, with chronic inflammation of the bile ducts, the risk of gallbladder epithelial dysplasia and gallbladder neoplasia increases. Sometimes an unusual itching is reported in patients with PSC due to bile salt retention and endogenous opioid ligand accumulation. In patients with PSC, due to biliary obstruction, the amount of conjugated bile acids in the intestine decreases. These conjugated bile acids are essential for lipid uptake and lipid-soluble compounds. Thus, in patients with PSC and reduced conjugated bile acids, absorption of fat-soluble vitamins (A, D, E, and K) diminishes, whereby the clinical symptoms associated with it can occur (16-18).

Genetic and Immune Factors in PSC

As previously discussed, there are several genetic and immune factors associated with PCS occurrence, progression, and response to treatment (19-22). Generally, it seems the most significant part of this influence is related to human leukocyte antigen (HLA) haplotypes (21, 23-26). For example, HLA-B8, HLA-DR3 (26), HLA-B, and HLA-DRB1 (27) have been shown to be associated with the risk of PSC development. In the liver transplant setting, donors with HLA-DRB1*07 increased the risk of graft failure, while the presence of HLA-DQB1*03, HLA-DRB1*04, and HLA-DQB1*07 in the recipient may have protective roles (28).

PSC treatment

Unfortunately, PSC pathogenesis is poorly understood; thus, PSC is generally considered as an idiopathic disease (2, 29) and there are few therapies available for it. Generally, the most effective treatment of PSC is liver transplantation, but there are also studies suggesting that medication therapy may have a positive effect in modifying the disease (2, 30).

Liver transplantation

Liver Transplantation is the only effective treatment proved so far for patients with advanced PSC. The usual time from diagnosis to liver transplantation is within the range of 20 to 25 years. Note that patients with PCS who have undergone liver transplant treatment are prone to acute and chronic cellular rejection (16, 31, 32). On the other hand, there is a significant recurrence of PSC (rPSC) in patients after orthotopic liver transplantation. Reportedly, PCS recurs in 30 to 50% of these individuals. With the recurrence of the disease in some patients, liver transplantation is
required again. Studies have also shown that recurrence of PSC can be seen more in patients with PSC-IBD. Nevertheless, liver transplantation is the only treatment for patients with advanced PCS (16, 28, 31, 32). It has also been suggested that patients at the end stage of liver disease (Mayo risk score > 15) should be referred for liver transplantation (33). Although HLA serotyping is not considered to have a significant influence on the outcome of PSC transplantation, studies suggest that there is an association between HLA serotyping and success of transplantation (19, 28, 34). For example HLA-B7, HLA-B57, HLA-B75, HLA-DR13, HLA-DQB1*03, HLA-DRB1*04, and HLA-DQB1*07, in the recipient and HLA-B55, HLA-B58, HLA-DRB1*07, and HLA-DR8 in the donor are associated with failure of liver transplantation treatment (28, 34).

Drug therapy of PSC

Although the pathogenesis of PSC has not been completely understood, there are some hypotheses of possible contributors such as intestinal microbiota (35, 36), immunological pathways (37, 38), and genetics (39-41). On the other hand, although there is no specific treatment for PSC, many studies have reported that some immunosuppressants and immunomodulatory drugs, antibiotics, and anti-inflammatory drugs can help control the disease and its complications (30, 42). Studies are suggesting that controlling and normalizing levels of alkaline phosphatase in the long-term would improve survival and reduce the risk of requiring liver transplantation (43, 44).

Anti-pruritus drugs

About half of patients diagnosed with PSC are asymptomatic at presentation (1, 11). However, in some cases patients complain of pruritus due to extrahepatic cholestasis. Pruritus can be extremely difficult to treat and often present at night. It has also been shown that histamine levels are also significantly elevated in PSC patients (102). Several studies have attempted to examine several drugs for pruritus management such as cholestyramine, Ursodeoxycholic acid, and rifampicin (47, 49). Recently, the use of melatonin has also been gaining attention in the management of gastrointestinal disease as well as anti-pruritus effect. It has been hypothesized that melatonin could reduce the itching among patients with chronic liver disease (103-104). The exact underlying mechanism of action of this agent is not yet fully understood. Although it has been suggested that melatonin could act via immunomodulatory, anti-inflammatory, and antioxidative effects. No large studies have been conducted on the use of this drug as a possible anti-pruritus agent of patients with PSC. Thus, future prospective randomized clinical trial studies are warranted to elucidate its role in reducing itching in these patients.

Ursodeoxycholic acid

Ursodeoxycholic acid (UDCA) is a derivative of chenodeoxycholate. It is a hydrophilic mammalian bile acid and the most extensively studied of all medical treatments for PSC (45, 46). Generally, UDCA is used for the treatment of cholestatic liver diseases. It acts mostly through protecting cholangiocytes, stimulating hepatobiliary secretion, and protecting hepatocytes against bile acid-induced apoptosis (47). On the other hand, UDCA is genotoxic, exerts aneugenic activity, and inhibits enzymes and processes such as DNA repair, p53, phagocytosis, and induction of nitric oxide synthetase (48). Although UDCA is the most commonly used and the most commonly studied drug for PSC, four meta-analyses of clinical trials indicated that despite the fact that UDCA improves liver biochemistry such as bilirubin and ALP, it has no effect on progression of disease, health-related quality of life, survival of PSC patients, and finally the requirement for liver transplantation. Also, UDCA does not show any noticeable effect on pruritus, fatigue, or cholangiocarcinoma development (49-52). Nevertheless, the follow-ups and trials of treatment were short as PSC is a slowly progressive disease and trials of 10 years or longer should be included (51). On the other hand, a meta-analysis study by Siddharth Singh et al. indicated that use of UDCA at a low dose (8–15 mg/kg/d) significantly decreased the risk of colorectal neoplasia in patients with PSC-IBD (53). Studies show that withdrawing UDCA can worsen biochemical test results and pruritus. In a study with 26 patients with PSC who stopped the medication after a period of treatment, a test 3 months after withdrawal of UDCA indicated approximately 61% increase in the average biochemical test and Mayo Risk Score (0.5 point increase from baseline) (54).

On the other hand, American Association for the Study of Liver Diseases in 2010 issued a guideline...
An update on treatment options for primary sclerosing cholangitis

Gastroenterol Hepatol Bed Bench 2020;13(2):115-124

recommending against the use of UDCA in the treatment of PSC (55).

Also, in other guidelines, UDCA is not recommended until further data are available on its efficacy and safety. The recommendation upon using UDCA in PSC is to stop UDCA in patients who are already taking it and restart it only if elevation of liver biochemicals such as bilirubin or alkaline phosphatase or a worsening in pruritus was observed and/or the patient experiences symptomatic improvement (54, 56-58).

Higher doses of PSC (28–30 mg/kg/day) results in an improved liver test, but it does not improve survival (59). Furthermore, studies show that high doses (28-30 mg/kg/day) of UDCA in long-term are associated with an increased risk of colorectal neoplasia in PSC patients (60). In a 5-year multicenter, randomized, controlled study by Olsson R et al. it was shown that there was no statistically significant difference in symptoms or quality of life when using a higher dose of UDCA in PSC patients (61). Based on these data, high-dose UDCA should be avoided in patients with PSC.

Meanwhile, a derivative of UDCA (24-norursodeoxycholic acid) has shown efficacy in an animal model of PSC (62, 63).

PSC is rare in pregnancy. Studies show that UDCA is safe to be used in pregnancy and shows no fetal effect; nevertheless there are not many reports of interventions in pregnancy and PSC (64, 65).

Combination of UDCA and metronidazole

Metronidazole (MTZ) is an antibiotic that can prevent PSC-like liver damage in vivo models (66). A randomized placebo-controlled study on 80 patients (41 UDCA/placebo and 39 UDCA/MTZ) examined the effect of UDCA and MTZ (UDCA/MTZ) compared with UDCA/placebo on the progression of PSC. A 3-year follow-up showed that patients consuming a combination of UDCA/MTZ had significantly lower serum alkaline phosphatase as compared to those using UDCA with placebo. The New Mayo Risk Score decreased remarkably only in the UDCA/MTZ group. In conclusion, combining MTZ with UDCA in PSC improved New Mayo Risk Score and levels of serum ALP, but no progression was observed in ERCP findings (67). Also, another study found that a combination of UDCA and MTZ tended to improve liver histological stage more than UDCA alone did (68).

Note that in Cockayne Syndrome, administration of MTZ is restricted and can cause fatal acute hepatic failure (69). Also, a study of one case revealed encephalopathy in a patient of Crohn's disease after an IV use of MTZ (70). Additionally, patients taking warfarin should consider warfarin-metronidazole interaction which can result in Intracerebral hemorrhage through the increase in S-warfarin concentrations (71).

Vancomycin

Vancomycin is an antibacterial agent obtained from streptomyces. It is a glycopeptide with a molecular mechanism of bacterial cell wall synthesis inhibition (72). One of the major toxicities of vancomycin is nephrotoxicity, in which demands taking proper medical actions such as therapeutic drug monitoring, changing dosing strategy, and antioxidantive therapy for preventing and treating vancomycin-induced acute kidney injury (73).

In small-scale studies, oral vancomycin has shown the possible successful ability in improving liver function tests in patients with pretransplant PSC through immunomodulatory and anti-inflammatory mechanisms (74). Moreover, a recent study on three patients with ulcerative colitis associated to PSC who were treated with 500mg of oral vancomycin twice a day as maintenance therapy, showed a significant clinical improvement and endoscopic remission (a Mayo endoscopic subscore of 0, six months after starting vancomycin). Also, oral vancomycin was tolerated well in these patients (75). In A triple blinded, randomized, placebo-controlled clinical trial on 29 patients with PSC, the efficacy of 125 mg oral vancomycin, four times a day was studied for 12 weeks. This study revealed an acceptable efficacy through a significant decline in the mean level of PSC Mayo risk score and the level of alkaline phosphatase (322.03% and 18.24% respectively) (76).

Glucocorticoids

Glucocorticoids are generally the most effective anti-inflammatory drugs available for the treatment of many chronic inflammatory diseases (77). In a study, five months of treatment with USDA was followed by adding glucocorticoid to the regimen in three different groups (two groups with different doses of 3 and 9 mg of budesonide and one group of 10 mg of prednisolone). In the prednisolone group, pruritus,
alkaline phosphatase, and IgG decreased significantly, but in the budesonide group, no significant clinical or liver biochemical changes were observed (78). Among the glucocorticoids, budesonide, with a primary role in detoxification and metabolism of bile acids via CYP3A4 and SULT2A1, was well-tolerated in patients with PSC, but it was not found beneficial at doses of 3 mg/day or 9 mg/day (79).

**Immunomodulators**

Azathioprine (AZT) and its metabolite 6-Mercaptopurine (6-MP), methotrexate (MTX), cyclosporine (CYA), and tacrolimus (Tace) are immune modifier drugs. Both AZT and 6-MP are used extensively in the treatment of IBD, i.e., UC and Crohn’s disease (80, 81). Generally, 6-MP acts as a purine antimetabolite, but AZT which is 6-MPs prodrug, has other modes of action such as prevention of proliferation in cells which is responsible for amplification of immune response by inhibiting several pathways in the biosynthesis of nucleic acids. The pharmacological action of AZT and 6-MP results in alteration of lymphocyte function, reduction in the number of lamina propria plasma cells, and inhibition of natural killer cell function (80, 82). On the other hand, MTX inhibits folate-dependent enzymes. In this regard, studies suggest that the molecular immunosuppression mechanism of MTX is by inhibition of amidophosphoribosyltransferase rather than inhibiting folate-dependent enzymes (83). Further, there are other hypotheses regarding the anti-inflammatory mechanism of MTX such as induction of Ag-specific immune tolerance (84), apoptosis, and clonal deletion of activated peripheral T cells (85). CYA and TACE are calcineurin inhibitors which helps improve the effectiveness of other drugs and their activity. They eventually result in inhibition of T-cell proliferation and generation of antigen-specific CD8+ cytotoxic T-lymphocytes (86).

The possible inflammatory mechanism of PSC suggests that use of Immunomodulators might be useful in treatment of relapse or for sustaining remission of PSC. A 41-month study of case series showed that progression of PSC in almost all cases stopped and even the condition of the disease improved in some patients using a combination of AZT, prednisolone, and UDCA (87). Despite the potential therapeutic role of MTX in the treatment of PSC, studies have not yet provided a robust results on its effectiveness. In addition, limitations in a clinical study of MTX such as size, duration, and participant heterogeneity have precluded any firm conclusions about the role of MTX in treatment of PSC (88). On the other hand, in a single controlled clinical trial, use of CSA significantly reduced serum alkaline phosphatase, bilirubin, alanine aminotransferase, and gamma globulin in Primary Biliary Cirrhosis (PBC), patients with side effects tolerated well. This suggests that CSA therapy is promising and warrants further evaluation (89). Also, in another study, TACE significantly reduced serum bilirubin and alkaline phosphatase level with no significant side effects in PSC patients and showed the potential role of TACE for the treatment of patients with PSC in feature (90).

**Anti-TNFs**

One of the major classes of immunosuppressants are anti-TNFs, which are the first biological agents in IBD, with studies showing their possible benefit in PSC (91). However, so far, in most studies on anti-TNF drugs, only adalimumab demonstrated a significant decrease in ADA-ALP, while other antagonists of TNF such as pentoxifylline, etanercept, and infliximab have shown very few significant improvements (91). These results finally suggest that anti-TNF biological therapies (excluding adalimumab) are not effective in the treatment of PSC, though further study is required to confirm the effectiveness of both adalimumab and other anti-TNFs (92).

**Vedolizumab**

In addition to anti-TNFs, vedolizumab, which targets alpha beta integrin, has shown controversial results (93-97), and in a most recent study, no significant biochemical respond was observed (98).

**Other drug therapies**

Although UCDA or other treatments reduce the biochemicals of the liver, most long-term studies indicate the fact that in the long run, most of the drug therapies do not reduce risks of mortality and requirement for liver transplantation. Nevertheless, a recent cohort study in Sweden revealed decreased risks of death or need for liver transplantation in patients with IBD-PSC using a combination of statins and azathioprine (99). Elsewhere, in an animal model, curcumin reduced liver damage and cholestasis, inhibited cholangiocyte proliferation as well as TNF-
alpha (100). However, clinical trials failed to show any significant improvement in cholestasis or symptoms of the disease (101). Moreover, rifaximin has also been studied as a treatment option for treating PSC. In a study, Tabibian et al. (105) indicated that 12 weeks of treatment with rifaximin did not show any improvement in terms of changes in liver enzymes, fatigue and quality of life of patients with PSC. Although several antibiotics have shown promising results in the management of PSC, other antibiotics such as rifaximin seem to be inefficacious for this indication.

**Conclusion**

PSC is a rare and poorly understood chronic cholestatic fibroinflammatory disease of the liver. It causes severe conditions such as malignancies, cirrhosis, and fibrotic liver diseases. Due to poor understanding of the disease pathways and the small number of participants in clinical studies, proposing a pharmacological treatment for PSC is challenging. Also, factors such as quality of life and the need for liver transplantation need long-term studies. Nevertheless, so far, there have been several promising drugs of pharmacological regimen which help control subclinical - and in some cases clinical - aspects of PSCnt.

**Conflict of interests**

The authors declare that they have no conflict of interest.

**References**

1. Fricker ZP, Lichtenstein DR. Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management. Dig Dis Sci 2019;64:632-42.
2. Kumagai J, Taida T, Ogasawara S, Nakagawa T, Iino Y, Shingyoji A, et al. Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients. PLoS One 2018;13:e0209352.
3. Stratton L, Williams MJ. Editorial: deciding when to intervene in primary sclerosing cholangitis. Aliment Pharmacol Ther 2018;48:484-5.
4. Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019;25:659-71.
5. Mertz A, Nguyen NA, Katsanos KH, Kwok RM. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Ann Gastroenterol 2019;32:124-33.
6. Gulamhusein AF, Eaton JE, Tabibian JH, Atkinson EJ, Juran BD, Lazaridis KN. Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD. Am J Gastroenterol 2016;111:705-11.
7. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48-54.
8. Folseraas T, Boberg KM. Cancer Risk and Surveillance in Primary Sclerosing Cholangitis. Clin Liver Dis 2016;20:79-98.
9. von Seth E, Ouchterlony H, Dobra K, Hjerpe A, Arnelo U, Haas S, et al. Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis. Liver Int 2019;39:382-8.
10. Vinnitskaya EV, Abdulkhakov SR, Abdurakhmanov DT, Alikhonov RB, Bakulin IG, Belousova EA, et al. Important problems in the diagnosis and treatment of primary sclerosing cholangitis (based on the Russian consensus on diagnosis and treatment autoimmune hepatitis. Moscow, 2018). Ter Arkh 2019;91:9-15.
11. Zenouzi R, Welle CL, Venkatesh SK, Schramm C, Eaton JE. Magnetic Resonance Imaging in Primary Sclerosing Cholangitis-Current State and Future Directions. Semin Liver Dis 2019;39:369-80.
12. Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best practice & research Clinical gastroenterology 2011;25:727-39.
13. Kummern M, Schrumpf E, Boberg KM. Liver abnormalities in bowel diseases. Best Pract Res Clin Gastroenterol 2013;27:531-42.
14. Charatcharoenwitthaya P, Lindor KD. Primary sclerosing cholangitis: diagnosis and management. Curr Gastroenterol Rep 2006;8:75-82.
15. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013;382:1587-99.
16. Singh S, Talwalkar JA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol 2013;11:898-907.
17. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol 2007;31:907-13.
18. Fialho A, Fialho A, Kochhar G, Shen B. The presence of primary sclerosing cholangitis in patients with ileal pouch anal-anastomosis is associated with an additional risk for vitamin D deficiency. Gastroenterol Rep 2015;4:320-4.
19. Fosby B, Naess S, Hov JR, Traherne J, Boberg KM, Trowsdale J, et al. HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation. World J Gastroenterol 2014;20:3986-4000.

20. Boberg KM, Spurkland A, Rocca G, Egeland T, Saarinen S, Mitchell S, et al. The HLA-DR3, DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol 2001;36:886-90.

21. Ferri PM, Simões E Silva AC, Campos Silva SL, de Aquino DJQ, Fagundes EDT, Marques de Miranda D, et al. The Role of Genetic and Immune Factors for the Pathogenesis of Primary Sclerosing Cholangitis in Childhood. Gastroenterol Res Pract 2016;2016:3905240.

22. Krawczyk M, Lammert F. Search for Genetic Modifiers of PSC: Time to Increase the Number of Needles in the Haystack. Ann Hepatol 2017;16:830-1.

23. Yliinen E, Salmela L, Perasaari J, Jaatinent T, Tenca A, Vapalalhti O, et al. Human leucocyte antigens B*08, DRB1*03 and DRB1*13 are significantly associated with autoimmune liver and biliary diseases in Finnish children. Acta Paediatr 2017;106:322-6.

24. Proehazka EJ, Terasaki PI, Park MS, Goldstein LI, Busuttil RW. Association of primary sclerosing cholangitis with HLA-DRW52a. N Engl J Med 1990;322:1842-4.

25. Chapman RW, Varghese Z, Gaul R, Patel G, Kinonin N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983;24:38-41.

26. Leidenius MH, Koskimies SA, Kellokumpu IH, Hockerstedt KA. HLA antigens in ulcerative colitis and primary sclerosing cholangitis. Apmis 1995;103:519-24.

27. Naess S, Lie BA, Melum E, Olsson M, Hov JR, Croucher PJ, et al. Refinement of the MHC risk map in a scandinavian primary sclerosing cholangitis population. PLoS One 2014;9:e114486.

28. Bajer L, Slavec A, Macinga P, Sticova E, Brezina J, Roder M, et al. Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease. World J Gastroenterol 2018;24:4939-49.

29. Tietz-Bogert PS, Kim M, Cheung A, Tabibian JH, Heimbach JK, Rosen CB, et al. Metabolomic Profiling of Portal Blood and Bile Reveals Metabolic Signatures of Primary Sclerosing Cholangitis. Int J Mol Sci 2018;19.

30. Shah A, Crawford D, Burger D, Martin N, Walker M, Talley NJ, et al. Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Semin Liver Dis 2019.

31. Goldberg DS. Liver transplant in patients with primary sclerosing cholangitis. Gastroenterol Hepatol 2016;12:127.

32. Ueda Y, Kaido T, Okajima H, Hata K, Anazawa T, Yoshizawa A, et al. Long-term prognosis and recurrence of primary sclerosing cholangitis after liver transplantation: a single-center experience. Transplant direct 2017;3.

33. Sirpal S, Chandok N. Primary sclerosing cholangitis: diagnostic and management challenges. Clin Exp Gastroenterol 2017;10:265-73.

34. Patel YA, Henson JB, Wilder JM, Zheng J, Chow SC, Berg CL, et al. The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis. Clin Transplant 2018;32:e13388.

35. Pereira P, Aho V, Arola J, Boyd S, Jokelainen K, Paulin L, et al. Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia. PLoS ONE 2017;12.

36. Tabibian JH, O’Hara SP, Trussoni CE, Tietz PS, Splinter PL, Mounajded T, et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology 2016;63:185-96.

37. Lampinen M, Vessby J, Fredriesson A, Wanders A, Rorsman F, Carlson M. High Serum sCD40 and a Distinct Colon C193 Profile in Ulcerative Colitis Associated With Primary Sclerosing Cholangitis. J Crohns Colitis 2019;13:341-50.

38. Langeneckert AE, Lunemann S, Martrus G, Salzberger W, Hess LU, Ziegler AE, et al. CCL21-expression and accumulation of CCR7(+) NK cells in livers of patients with primary sclerosing cholangitis. Eur J Immunol 2019;49:758-69.

39. Paziewska A, Habior A, Rogowska A, Zych W, Goryka K, Karczmarski J, et al. A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients. BMC Med Genomics 2017;10:1-9.

40. Kempinska-Podhorodecka A, Milkiewicz M, Jabłonski D, Milkiewicz P, Wunsch E. Apal polymorphism of Vitamin D receptor affects health-related quality of life in patients with primary sclerosing cholangitis. PLoS ONE 2017;12.

41. Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet 2017;49:269-73.

42. Lynch KD, Keshav S, Chapman RW. The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Curr Hepatol Rep 2019;18:115-26.

43. Hilscher M, Enders F, Carey E, Lindor K, Tabibian JH. Normalization of Serum Alkaline Phosphatase Is a Biomarker of Decreased Major Adverse Event Risk in Primary Sclerosing Cholangitis: Presidential Poster 2015;110:S1-2.

44. Hilscher M, Enders FB, Carey EJ, Lindor KD, Tabibian JH. Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. Ann Hepatol 2016;15:246-53.
**122 An update on treatment options for primary sclerosing cholangitis**

45. Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009;50:1721-34.

46. Broughton G. Chenodeoxycholate: The Bile Acid. The Drug. A Review. Am J Med Sci 1994;307:54-63.

47. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36:525-31.

48. Kob MA. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. Int J Mol Sci 2012;13:8882-914.

49. Triantos CK, Koukias NM, Nikolopoulos VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011;34:901-10.

50. Shi J, Li Z, Zeng X, Lin Y, Xie WF. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res 2009;39:865-73.

51. Saffioti F, Gurusamy KS, Hawkins N, Toon CD, Tsochatzis E, Davidson BR, et al. Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:Cd011343.

52. Othman MO, Dunkelberg J, Roy PK. Ursodeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review. Arab J Gastroenterol 2012;13:103-10.

53. Singh S, Khanna S, Pardi DS, Loftsus EV, Jr., Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013;19:1631-8.

54. Wunsch E, Trottier J, Milkiewicz M, Raszeja-Wyszomirska J, Hirschfield GM, Barbier O, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology 2014;60:931-40.

55. Chapman R, Favery J, Kallooo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-78.

56. Tabibian JH, Lindor KD. Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). Hepatology 2014;60:785-8.

57. Lindstrom L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013;11:841-6.

58. Talwalkar JA, Chapman RW. The Resurgence of Serum Alkaline Phosphatase as a Surrogate Biomarker for Prognosis in Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol 2013;11:847-9.

59. Lindor KD, Kowdley KV, Luketic VAC, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14.

60. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106:1638-45.

61. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-72.

62. Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 2017;67:549-58.

63. Dickson I. Ursodeoxycholic acid derivative: safe and effective. Nat Rev Gastroenterol Hepatol 2017;14:386.

64. Kammeijer CQ, De Man RA, De Groot CJM. Primary sclerosing cholangitis and pregnancy. Clin Pract 2011;1:e55-e.

65. Palma J, Reyes H, Ribalta J, Hernandez I, Sandoval L, Almuna R, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997;27:1022-8.

66. Lichtman SN, Keku J, Schwab JH, Sartor RB. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology 1991;100:513-9.

67. Farkkila M, Karvon Al, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004;40:1379-86.

68. Zhu GQ, Shi KQ, Huang GQ, Wang Lr, Lin YQ, Braddock M, et al. A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. Oncotarget 2015;6:26757-69.

69. Wilson BT, Strong A, O'Kelly S, Munkley J, Stark Z. Metronidazole Toxicity in Cockayne Syndrome: A Case Series. Pediatrics. 2015;136:e706-8.

70. Kim J, Chun J, Park YJ, Hong SW, Lee JY, Kang JW, et al. Metronidazole-induced encephalopathy in a patient with Crohn's disease. Intestinal research 2017;15:124-9.

71. Howard-Thompson A, Hurdle AC, Arnold LB, Finch CK, Sands C, Self TH. Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. Am J Geriatr Pharmacother 2008;6:33-6.

72. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42:S35-9.
73.Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab 2016;7:136-47.

74.Hey P, Lokan J, Johnson P, Gow P. Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation. BMJ Case Rep 2017;221165.

75.de Chambrun GP, Nachury M, Funakoshi N, Gerard R, Bismuth M, Valats JC, et al. Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2018;30:1247-52.

76.Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromilou MK, Azizi Z. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study. J Gastrointestin Liver Dis 2016;25:457-64.

77.Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011;163:29-43.

78.van Hoogstraten HJ, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000;95:2015-22.

79.Goldstein J, Levy C. Novel and emerging therapies for cholestatic liver diseases. Liver Int 2018;38:1520-35.

80.Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001;15:1699-708.

81.Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011;17:4166-73.

82.Cseuz R, Panayi GS. The inhibition of NK cell function by mercaptopurine during the treatment of patients with rheumatoid arthritis. Br J Rheumatol 1990;29:358-62.

83.Sant ME, Lyons SD, Phillips L, Christopherson RI. Antifolates induce inhibition of amido phosphoribosyltransferase in leukemia cells. J Biol Chem 1992;267:11038-45.

84.Joly MS, Martin RP, Mitra-Kaushik S, Phillips L, D’Angona A, Richards SM, et al. Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa. J Immunol 2014;193:3947-58.

85.Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998;102:322-8.

86.Hartono C, Muthukumar T, Suthanthiran M. Immunosuppressive drug therapy. Cold Spring Harb Perspect Med 2013;3:a015487-a.

87.Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, zum Buschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursoxiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999;131:943-6.

88.Novak K, Swain MG. Role of Methotrexate in the Treatment of Chronic Cholestatic Disorders. Clin Liver Dis 2008;12:81-96.

89.Wiesner RH, Ludwig J, Lindor KD, Jorgensen RA, Baldus WP, Homburger HA, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990;322:1419-24.

90.Van Thiel DH, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455-9.

91.Lynch KD, Keshav S, Chapman RW. The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Curr Hepatol Rep 2019;18:115-26.

92.Tse CS, Loftus EV, Jr., Raffals LE, Gossard AA, Lightner AL. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2018;48:190-5.

93.Westerveld D, Grajo B, Beattie L, Glover S. Vedolizumab: a novel medical intervention in the treatment of primary sclerosing cholangitis. BMJ Case Rep 2017;202351.

94.Coletta M, Paroni M, Caprioli F. Successful Treatment With Vedolizumab in a Patient With Chronic Refractory Pouchitis and Primary Sclerosing Cholangitis. J Crohns Colitis 2017;11:1507-8.

95.Williamson KD, Slevin S, Willberg C, Chapman RW, Klenerman P, Keshav S. Clinical and Translational Outcomes of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease Receiving Vedolizumab. Gastroenterology 2017;152:S1186-7.

96.Williamson KD, Lytvyak E, de Krijger M, Trivedi P, Estes D, Yu L, et al. - International Experience of Vedolizumab in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. Gastroenterology 2018;154:S1097-8.

97.Christensen B, Gibson PR, Rubin DT. Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease—Authors’ reply. Aliment Pharmacol Ther 2018;47:1423-4.

98.Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019.

99.Stokkeland K, Hoijer J, Bottai M, Soderberg-Lofdal K, Bergquist A. Statin Use Is Associated With Improved Outcomes of Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol 2019;17:1860-6.e1.
100. Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, et al. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010;59:521-30.

101. Eaton JE, Nelson KM, Gossard AA, Carey EJ, Tabibian JH, Lindor KD, et al. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. Scand J Gastroenterol 2019;54:633-9.

102. Bhlerao A, Mannu GS. Management of pruritus in chronic liver disease. Dermatol Res Pract 2015;2015:295891.

103. Iravani S, Eslami P, Dooghaie Moghadam A, Moazzami B, Mehrvar A, Hashemi MR, et al. The Role of Melatonin in Colorectal Cancer. J Gastrointest Cancer 2019:2.

104. Esmaeili A, Namazi S. Is melatonin effective for pruritus caused by liver disease? Med Hypotheses 2018;121:177-9.

105. Tabibian JH, Gossard A, El-Youssef M, Eaton JE, Petz J, Jorgensen R, et al. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. Am J Ther 2017;24:e56-63.